An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18 F-PM-PBB3 ( 18 F-APN-1607).
Autor: | Tagai K; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan. Electronic address: tagai.kenji@qst.go.jp., Ikoma Y; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Endo H; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Debnath OB; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Seki C; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Matsuoka K; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Matsumoto H; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Oya M; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Hirata K; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Shinotoh H; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Takahata K; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan., Kurose S; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan., Sano Y; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan., Ono M; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Shimada H; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan., Kawamura K; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Zhang MR; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan., Takado Y; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan. Electronic address: takado.yuhei@qst.go.jp., Higuchi M; Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan. |
---|---|
Jazyk: | angličtina |
Zdroj: | NeuroImage [Neuroimage] 2022 Dec 01; Vol. 264, pp. 119763. Date of Electronic Publication: 2022 Nov 24. |
DOI: | 10.1016/j.neuroimage.2022.119763 |
Abstrakt: | Positron emission tomography (PET) with 18 F-PM-PBB3 ( 18 F-APN-1607, 18 F-Florzolotau) enables high-contrast detection of tau depositions in various neurodegenerative dementias, including Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). A simplified method for quantifying radioligand binding in target regions is to employ the cerebellum as a reference (CB-ref) on the assumption that the cerebellum has minimal tau pathologies. This procedure is typically valid in AD, while FTLD disorders exemplified by progressive supranuclear palsy (PSP) are characterized by occasional tau accumulations in the cerebellum, hampering the application of CB-ref. The present study aimed to establish an optimal method for defining reference tissues on 18 F-PM-PBB3-PET images of AD and non-AD tauopathy brains. We developed a new algorithm to extract reference voxels with a low likelihood of containing tau deposits from gray matter (GM-ref) or white matter (WM-ref) by a bimodal fit to an individual, voxel-wise histogram of the radioligand retentions and applied it to 18 F-PM-PBB3-PET data obtained from age-matched 40 healthy controls (HCs) and 23 CE, 40 PSP, and five other tau-positive FTLD patients. PET images acquired at 90-110 min after injection were averaged and co-registered to corresponding magnetic resonance imaging space. Subsequently, we generated standardized uptake value ratio (SUVR) images estimated by CB-ref, GM-ref and WM-ref, respectively, and then compared the diagnostic performances. GM-ref and WM-ref covered a broad area in HCs and were free of voxels located in regions known to bear high tau burdens in AD and PSP patients. However, radioligand retentions in WM-ref exhibited age-related declines. GM-ref was unaffected by aging and provided SUVR images with higher contrast than CB-ref in FTLD patients with suspected and confirmed corticobasal degeneration. The methodology for determining reference tissues as optimized here improves the accuracy of 18 F-PM-PBB3-PET measurements of tau burdens in a wide range of neurodegenerative illnesses. Competing Interests: Declaration of Competing Interest Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). (Copyright © 2022. Published by Elsevier Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |